Andere talen C4 Therapeutics, Inc.

Aandelen

CCCC

US12529R1077

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,17 ^USD	-1,12%		-8,18%	+9,20%

08/04	C4 Therapeutics, Inc. presenteert nieuwe preklinische gegevens voor CFT1946 die superieure activiteit als afzonderlijk middel benadrukken ten opzichte van klinisch goedgekeurde BRAF-remmer-standaardzorgcombinaties op de American Association for Cancer Research Annual Meeting 2024	CI
04/03	C4 Therapeutics werkt samen met het Duitse Merck KGaA om onderzoek naar doelgerichte therapieën voor kanker te bevorderen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum	09/04
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08/04
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08/04
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	18/03
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024	06/03
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	05/03
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	05/03
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	04/03
C4 Therapeutics : Corporate Presentation – March 2024	04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	04/03
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22/02
North American Morning Briefing : Stock Futures -2-	21/02
North American Morning Briefing : Microsoft Kicks -2-	30/01
C4 Therapeutics Shares Jump After JPMorgan Upgrade	29/01
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines	09/01
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines	09/01
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen C4 Therapeutics, Inc.

Aandelen

CCCC

US12529R1077

Andere talen

Filters